0001415889-24-019168.txt : 20240703 0001415889-24-019168.hdr.sgml : 20240703 20240703161124 ACCESSION NUMBER: 0001415889-24-019168 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240701 FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ticho Barry CENTRAL INDEX KEY: 0001780088 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38938 FILM NUMBER: 241100217 MAIL ADDRESS: STREET 1: C/O STOKE THERAPEUTICS, INC. STREET 2: 45 WIGGINS AVE CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Stoke Therapeutics, Inc. CENTRAL INDEX KEY: 0001623526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 471144582 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-430-8200 MAIL ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141028 4 1 form4-07032024_080719.xml X0508 4 2024-07-01 0001623526 Stoke Therapeutics, Inc. STOK 0001780088 Ticho Barry C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE BEDFORD MA 01730 false true false false CHIEF MEDICAL OFFICER 1 Common Stock 2024-07-01 4 M 0 10000 0.60 A 12485 D Common Stock 2024-07-01 4 S 0 10000 13.7458 D 2485 D Stock Option (Right to Buy) 0.60 2024-07-01 4 M 0 10000 0 D 2028-04-02 Common Stock 10000 50000 D The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.47 to $14.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. /s/ Jonathan Allan, Attorney-in-Fact 2024-07-03